Ranirestat
Modify Date: 2024-01-02 21:20:26
Ranirestat structure
|
Common Name | Ranirestat | ||
|---|---|---|---|---|
| CAS Number | 147254-64-6 | Molecular Weight | 420.18900 | |
| Density | 1.83g/cm3 | Boiling Point | 702.7ºC at 760mmHg | |
| Molecular Formula | C17H11BrFN3O4 | Melting Point | N/A | |
| MSDS | Chinese USA | Flash Point | 378.8ºC | |
| Symbol |
GHS07 |
Signal Word | Warning | |
Use of RanirestatRanirestat (AS-3201) is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy. |
| Name | (3R)-2'-[(4-bromo-2-fluorophenyl)methyl]spiro[pyrrolidine-3,4'-pyrrolo[1,2-a]pyrazine]-1',2,3',5-tetrone |
|---|---|
| Synonym | More Synonyms |
| Description | Ranirestat (AS-3201) is an aldose reductase inhibitor being developed for the treatment of diabetic neuropathy. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.83g/cm3 |
|---|---|
| Boiling Point | 702.7ºC at 760mmHg |
| Molecular Formula | C17H11BrFN3O4 |
| Molecular Weight | 420.18900 |
| Flash Point | 378.8ºC |
| Exact Mass | 418.99200 |
| PSA | 91.97000 |
| LogP | 1.52790 |
| Vapour Pressure | 1.36E-19mmHg at 25°C |
| Index of Refraction | 1.749 |
| Storage condition | 2-8℃ |
| Symbol |
GHS07 |
|---|---|
| Signal Word | Warning |
| Hazard Statements | H315-H319-H335 |
| Precautionary Statements | P280-P304 + P340 + P312-P305 + P351 + P338-P337 + P313 |
| RIDADR | NONH for all modes of transport |
| RTECS | WH1441246 |
| Precursor 1 | |
|---|---|
| DownStream 0 | |
| (3R)-2'-(4-bromo-2-fluorobenzyl)spiro[pyrrolidin-3,4'(1'H)-pyrrolo[1,2-a]pyrazin]-1',2,3',5(2'H)-tetraone |
| Ranirestat |
| Ranirestat (JAN/INN) |
| (R)-2-(4-bromo-2-fluorobenzyl)spiro[1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-4,3'-pyrrolidine]-1,2',3,5'-tetrone |
| R-(-)-2-(4-bromo-2-fluorobenzyl)-1,2,3,4-tetrahydro[1,2-a]pyrrolopyridine-4-spiro-3'-pyrrolidine-1,2',3'5'-tetraone |
| SX-3202 |
| (3R)-2'-(4-bromo-2-fluorobenzyl)spiro[pyrrolidine-3,4'(1'H)-pyrrolo[1,2-a]pyrazine]-1',2,3',5(2H')-tetraone |
| AS-3201 |
| SX 3030 |